By Laurel Damashek
Glomerular disease care improves when the people who read the biopsy, the people who treat the patient and the people who study the immune system learn together. That conviction shaped the 2026 Imperial & ISGD Glomerular Disease Preceptorship, held November 5 and 6 at Scale Space on Imperial College London's White City Campus. Twenty-seven participants and faculty from five countries joined Scientific Co-Chairs Professor Liz Lightstone and Professor Stephen McAdoo for two days devoted to C3 glomerulopathy (C3G), immune complex membranoproliferative glomerulonephritis (IC-MPGN), and the wider field of complement-mediated kidney disease.
This program was organized by the International Society of Glomerular Disease and funded by an educational grant from Sobi. Sobi had no role in its content, its faculty or the selection of participants.
The faculty brought nephrology, pathology, rheumatology and immunology to a single table. Marina Botto (Imperial College London), a rheumatologist, opened with complement in health and disease, and Matthew Pickering (Imperial College London) traced the evolving diagnosis and treatment of C3G and IC-MPGN. David Kavanagh, who leads the UK's National Renal Complement Therapeutics Centre, asked when thrombotic microangiopathy is truly complement-driven and when infection-related glomerulonephritis only appears to be. Maria Prendecki and Tabitha Turner-Stokes brought the innate immune view, from neutrophils and neutrophil extracellular traps (NETs) to macrophages in injury and repair, and Charles Pusey presented anti-GBM disease as an archetypal autoimmune kidney disease. Pathologists Terry Cook, Candice Roufosse, Andrew Smith and Naomi Simmonds worked alongside nephrologists throughout. Further sessions covered complement in the kidney biopsy, complement diagnostics beyond the biopsy, and infection risks in the era of complement inhibition. Two open discussions steered the sessions: what do we mean by a "complement-mediated" kidney disease, and what can other glomerular diseases, from lupus nephritis to anti-GBM disease, teach us about C3G and IC-MPGN?
Friday's case discussions showed the model at its best. The whole group worked through the cases together in one room, and the team teaching was memorable: a pathologist described the features on the biopsy while a nephrologist pointed them out, so participants saw the tissue and the clinical question together. A complex, refractory vasculitis case prompted detailed discussion of next steps, and another conversation turned to shared decision-making with patients who have glomerulonephritis and are considering pregnancy. In the words of Professor McAdoo, “the highlight was working through real cases at the interface of clinical care and pathology – a great example of the multidisciplinary learning that ISGD exists to support."
Scale Space suited the work. A joint venture between Imperial and Blenheim Chalcot, it is home to more than 100 digital tech and life science companies and aims to be among the world's best innovation ecosystems. Glomerular disease care is changing in the same way, as new diagnostics and treatments reach the clinic and ask pathology, immunology and clinical judgment to work in concert.
Several lessons stood out. Glomerular disease rarely fits inside one specialty, and nephrologists, pathologists, rheumatologists and other relevant specialists reach better answers together than apart. Clues also arise outside the kidney clinic, since ophthalmologic and dental symptoms can steer a diagnosis. A session on building a specialist service, with shared pathology review, regular multidisciplinary team meetings and referral networks, led into a closing panel on what a C3G and IC-MPGN center of excellence should look like. A theme throughout every condition discussed: which biomarkers accurately represent disease activity and long-term risk? Clinicians still need better ways to tell how active a disease is today and what it means for a person's future kidney health, and answering it will take the collaboration this program modeled.
Our thanks to Liz Lightstone and Stephen McAdoo for hosting, to Imperial College London for its welcome, and to every faculty member and participant for their time and questions. ISGD preceptorships bring the newest clinical practice and research to nephrologists caring for people with glomerular disease. We look forward to holding the next one at University Medical Center Hamburg-Eppendorf at the beginning of December. To learn more or get involved with the Preceptorships program, contact preceptorships@is-gd.org.